UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000044074 |
|---|---|
| Receipt number | R000050318 |
| Scientific Title | Special drug use survey of DARZQURO Combination Subcutaneous Injection (Multiple Myeloma) |
| Date of disclosure of the study information | 2021/06/01 |
| Last modified on | 2021/05/17 11:53:56 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Special drug use survey of DARZQURO Combination Subcutaneous Injection (Multiple Myeloma)
Acronym
DRQ1L
Scientific Title
Special drug use survey of DARZQURO Combination Subcutaneous Injection (Multiple Myeloma)
Scientific Title:Acronym
DRQ1L
Region
| Japan |
Condition
Condition
Multiple Myeloma
Classification by specialty
| Hematology and clinical oncology |
Classification by malignancy
Malignancy
Genomic information
NO
Objectives
Narrative objectives1
To investigate safety profile of Daratumumab SC under the actual clinical practice in Japan.
Basic objectives2
Safety
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
Safety(Adverse Drug Reaction)
Key secondary outcomes
Base
Study type
Observational
Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| Not applicable |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
Patients who have never treated with Darzalex IV and treated with this drug for the first time according to the indication.
Patients who understand the contents of this survey and consent to participate in this survey.
Key exclusion criteria
Patients with a history of the use of Daratumumab.
Target sample size
200
Research contact person
Name of lead principal investigator
| 1st name | MORIYUKI |
| Middle name | |
| Last name | MIYASATO |
Organization
Janssen Pharmaceutical K.K.
Division name
Safety Risk Management Dept.
Zip code
101-0065
Address
5-2, Nishi-Kanda 3-chome, Chiyoda-ku, Tokyo
TEL
03-4411-5136
MMIYASAT@its.jnj.com
Public contact
Name of contact person
| 1st name | HIROKAZU |
| Middle name | |
| Last name | SHIRAI |
Organization
Janssen Pharmaceutical K.K.
Division name
Safety Risk Management Dept.
Zip code
101-0065
Address
5-2, Nishi-Kanda 3-chome, Chiyoda-ku, Tokyo
TEL
03-4411-5136
Homepage URL
hshirai3@ITS.JNJ.com
Sponsor or person
Institute
Janssen Pharmaceutical K.K.
Institute
Department
Personal name
Funding Source
Organization
Janssen Pharmaceutical K.K.
Organization
Division
Category of Funding Organization
Profit organization
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Janssen Pharmaceutical K.K.
Address
5-2, Nishi-Kanda 3-chome, Chiyoda-ku, Tokyo
Tel
03-4411-5136
kimai4@its.jnj.com
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2021 | Year | 06 | Month | 01 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Preinitiation
Date of protocol fixation
| 2021 | Year | 04 | Month | 20 | Day |
Date of IRB
Anticipated trial start date
| 2021 | Year | 06 | Month | 01 | Day |
Last follow-up date
| 2023 | Year | 11 | Month | 30 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Nothing in particular
Management information
Registered date
| 2021 | Year | 04 | Month | 28 | Day |
Last modified on
| 2021 | Year | 05 | Month | 17 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000050318
